Denali Therapeutics

General Information

Our goal is to discover and develop therapeutics to defeat degeneration. Neurodegeneration represents one of the most significant unmet medical needs of our time, with few effective therapeutic options available for patients with Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, or ALS, and other neurodegenerative diseases. The burden of these diseases to patients and society is massive. We believe the time is right to make a strong and ambitious effort to defeat neurodegeneration. We believe that we can succeed in a field that has seen limited success in the past, because of our team of experienced and passionately dedicated scientists and drug developers, our focused scientific strategy, and our proprietary blood-brain barrier, or BBB, platform delivery technology. We are developing a broad portfolio of targeted therapeutic candidates for neurodegenerative diseases and have recently initiated our first clinical trials.

Employees: 125
Founded: 2015
Contact Information
Address 151 Oyster Point Blvd., 2nd Floor, South San Francisco, CA 94080, US
Phone Number (650) 866-8548.
Web Address
View Prospectus: Denali Therapeutics
Financial Information
Market Cap $1583.6mil
Revenues $0 mil (last 12 months)
Net Income $-84.8 mil (last 12 months)
IPO Profile
Symbol DNLI
Exchange NASDAQ
Shares (millions): 13.9
Price range $18.00 - $18.00
Est. $ Volume $250.0 mil
Manager / Joint Managers Goldman Sachs/ Morgan Stanley/ J.P. Morgan
CO-Managers Evercore ISI
Expected To Trade: 12/8/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change